A Phase 2 Study of Bezuclastinib (CGT9486), an Oral, Selective, and Potent KIT D816V Inhibitor, in Adult Patients with Advanced Systemic Mastocytosis (AdvSM)

Systemic mastocytosis (SM) is characterized by excessive accumulation of mast cells in bone marrow and other extracutaneous tissues encompassing a spectrum of variants ranging from non-advanced to advanced disease (Shomali et al, 2018). Advanced systemic mastocytosis (AdvSM) is an aggressive and lif...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2021-11, Vol.138 (Supplement 1), p.3636-3636
Main Authors: Gotlib, Jason, George, Tracy I., Deininger, Michael W., Tashi, Tsewang, Pullarkat, Vinod A., Bose, Prithviraj, Payumo, Francis, Pilla, Amanda, Jolin, Hina, Sachs, Jessica, DeAngelo, Daniel J.
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Systemic mastocytosis (SM) is characterized by excessive accumulation of mast cells in bone marrow and other extracutaneous tissues encompassing a spectrum of variants ranging from non-advanced to advanced disease (Shomali et al, 2018). Advanced systemic mastocytosis (AdvSM) is an aggressive and life-threatening form of SM with an overall survival from
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2021-145928